Ayden I Scheim1, Greta R Bauer2, Mostafa Shokoohi2. 1. Department of Epidemiology & Biostatistics, Schulich School of Medicine & Dentistry, The University of Western Ontario, K201 Kresge Building, London, ON N6A 5C1, Canada. Electronic address: ascheim@uwo.ca. 2. Department of Epidemiology & Biostatistics, Schulich School of Medicine & Dentistry, The University of Western Ontario, K201 Kresge Building, London, ON N6A 5C1, Canada.
Abstract
INTRODUCTION: We identified the prevalence and correlates of past-year illicit drug use among transgender people in Ontario, Canada, and disparities with the age-standardized non-transgender population. METHODS: Data on transgender persons aged 16+ (n=406) were obtained from Trans PULSE, a respondent-driven sampling (RDS) survey (2009-2010). Overall and sex-specific estimates of past-year drug use (cocaine and amphetamines, based on data availability) in the reference population were obtained from Ontario residents aged 16+ (n=39, 980) in the Canadian Community Health Survey (2009-2010), and standardized to the overall and gender-specific transgender age distributions. For regression analyses with Trans PULSE data, past-year drug use included drug types associated with high risk of physical, psychological, and social harm to the user, and RDS-II weights were applied to frequencies and prevalence ratios (PR) derived from blockwise logistic regression models. RESULTS: An estimated 12.3% (95% CI: 7.7, 17.0) of transgender Ontarians had used at least one of the specified drugs in the past year, with no significant difference by gender identity. Transgender Ontarians were more likely to use both cocaine (standardized prevalence difference; SPD=6.8%; 95% CI=1.6, 10.9) and amphetamines (SPD=SPD=1.3%, 95% CI=0.2, 3.1) as compared to the age-standardized non-transgender population. History of transphobic assault, homelessness or underhousing, and sex work were associated with greater drug use among transgender persons. CONCLUSIONS: The prevalence of cocaine and amphetamine use among transgender people in Ontario, Canada was higher than in the age-standardized reference population. Social exclusion predicted within-group variation in drug use among transgender persons.
INTRODUCTION: We identified the prevalence and correlates of past-year illicit drug use among transgender people in Ontario, Canada, and disparities with the age-standardized non-transgender population. METHODS: Data on transgender persons aged 16+ (n=406) were obtained from Trans PULSE, a respondent-driven sampling (RDS) survey (2009-2010). Overall and sex-specific estimates of past-year drug use (cocaine and amphetamines, based on data availability) in the reference population were obtained from Ontario residents aged 16+ (n=39, 980) in the Canadian Community Health Survey (2009-2010), and standardized to the overall and gender-specific transgender age distributions. For regression analyses with Trans PULSE data, past-year drug use included drug types associated with high risk of physical, psychological, and social harm to the user, and RDS-II weights were applied to frequencies and prevalence ratios (PR) derived from blockwise logistic regression models. RESULTS: An estimated 12.3% (95% CI: 7.7, 17.0) of transgender Ontarians had used at least one of the specified drugs in the past year, with no significant difference by gender identity. Transgender Ontarians were more likely to use both cocaine (standardized prevalence difference; SPD=6.8%; 95% CI=1.6, 10.9) and amphetamines (SPD=SPD=1.3%, 95% CI=0.2, 3.1) as compared to the age-standardized non-transgender population. History of transphobic assault, homelessness or underhousing, and sex work were associated with greater drug use among transgender persons. CONCLUSIONS: The prevalence of cocaine and amphetamine use among transgender people in Ontario, Canada was higher than in the age-standardized reference population. Social exclusion predicted within-group variation in drug use among transgender persons.
Authors: Anne M Gadermann; Mohammad Ehsanul Karim; Monica Norena; Scott D Emerson; Anita M Hubley; Lara B Russell; Rosane Nisenbaum; Stephen W Hwang; Tim Aubry; Anita Palepu Journal: J Urban Health Date: 2020-04 Impact factor: 3.671
Authors: Hyemin Lee; Kevin K Tomita; Janice M Habarth; Don Operario; Horim Yi; Sungsub Choo; Seung-Sup Kim Journal: Int J Transgend Health Date: 2020-04-11
Authors: Madeline C Frost; John R Blosnich; Keren Lehavot; Jessica A Chen; Anna D Rubinsky; Joseph E Glass; Emily C Williams Journal: J Addict Med Date: 2021 Jul-Aug 01 Impact factor: 3.702
Authors: Hill L Wolfe; Katie B Biello; Sari L Reisner; Matthew J Mimiaga; Sean R Cahill; Jaclyn M W Hughto Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852
Authors: Bruna L Seibel; Bruno de Brito Silva; Anna M V Fontanari; Ramiro F Catelan; Ana M Bercht; Juliana L Stucky; Diogo A DeSousa; Elder Cerqueira-Santos; Henrique C Nardi; Silvia H Koller; Angelo B Costa Journal: Front Psychol Date: 2018-03-27
Authors: Leo Rutherford; Aeron Stark; Aidan Ablona; Benjamin J Klassen; Robert Higgins; Hanna Jacobsen; Christopher J Draenos; Kiffer G Card; Nathan J Lachowsky Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Tommy Hana; Kat Butler; L Trevor Young; Gerardo Zamora; June Sing Hong Lam Journal: Bull World Health Organ Date: 2021-01-21 Impact factor: 9.408
Authors: Martin St-Jean; Kalysha Closson; Travis Salway; Kiffer Card; Thomas L Patterson; Robert S Hogg; Viviane D Lima Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2021-07-19 Impact factor: 4.328